FibroFind Acquisition Accelerates Global Growth with Vespa Capital
Deal News | May 13, 2025 | B Daily
FibroFind, a Newcastle University spin-out specializing in pre-clinical testing for fibrotic diseases, has been acquired by private equity firm Vespa Capital. Known for its patented platform that uses real human tissue for precise drug testing, FibroFind is poised for global expansion. The acquisition will allow FibroFind to diversify its services and broaden its scientific reach in the drug development market. As the pharmaceutical industry increasingly shifts from animal models to human-relevant testing, FibroFind's technology provides vital data for the successful advancement of clinical trials. Vespa Capital's support is set to enhance FibroFind’s operational scalability. Professor Jelena Mann, CEO of FibroFind, and David Forbes, partner at Vespa Capital, highlight the strategic partnership as crucial for accelerating the firm's growth trajectory.
Sectors
- Biotechnology
- Private Equity
- Life Sciences
Geography
- United Kingdom – FibroFind is a spin-out from Newcastle University, located in the UK, and is central to the acquisition discussed.
Industry
- Biotechnology – FibroFind operates in the biotechnology sector, focusing on drug development and pre-clinical testing for fibrotic diseases.
- Private Equity – Vespa Capital, a private equity firm, is involved in the acquisition, facilitating FibroFind's global expansion.
- Life Sciences – The life sciences sector is relevant as FibroFind's platform provides innovative solutions to enhance drug development and reduce reliance on animal models.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| FibroFind | Target Company | Companies | A biotechnology company specializing in pre-clinical testing for fibrotic diseases. |
| Vespa Capital | Bidding Company | Companies | A private equity firm acquiring FibroFind to support its global expansion and service diversification. |
| Professor Jelena Mann | Chief Executive and Co-founder of FibroFind | People | CEO of FibroFind and Professor of Epigenetics at Newcastle University. |
| David Forbes | Partner at Vespa Capital | People | Partner at Vespa Capital and spokesperson regarding the acquisition. |